Dorval Allison
Known title: DirectorCIK: 0001625110
Associated companies
Transaction History
| PBYI | ▼ Sell | Open Market | 11,610 | $84K | 6/12/2026 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2026 | View on chart |
| PBYI | ▼ Sell | Open Market | 11,610 | $39K | 6/13/2025 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2025 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/18/2024 | View on chart |
| PBYI | ▼ Sell | Open Market | 11,000 | $37K | 6/13/2024 | View on chart |
| PBYI | ▼ Sell | Open Market | 10,000 | $35K | 6/13/2023 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/13/2023 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4)
Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4). Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.